Ask about this productRelated genes to: DSCAM antibody
- Gene:
- DSCAM NIH gene
- Name:
- DS cell adhesion molecule
- Previous symbol:
- -
- Synonyms:
- CHD2-42, CHD2-52
- Chromosome:
- 21q22.2
- Locus Type:
- gene with protein product
- Date approved:
- 1998-06-10
- Date modifiied:
- 2016-10-05
Related products to: DSCAM antibody
Related articles to: DSCAM antibody
- The dual-specificity, tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is intensively studied because of its implication in numerous human diseases (Down syndrome, Alzheimer's disease, type 2 diabetes, myocardial infarction, various cancers and leukaemia, etc.). Several GWAS studies have identified DYRK1A as a risk factor for Parkinson's disease (PD). DYRK1A indeed phosphorylates at least 20 proteins clearly involved in PD: AMPH, CASP9, DYN1, FOXO, GSK3B, MAP1B, MAPT, MEF2D, NFAT, TP53, PRKN, PLK2, RABs, RCAN1, SEPT4, SNCA, STAT3, SYNJ1, TOM70, WASL. Several other proteins involved in PD interact with DYRK1A: calpains, DSCAM, REST/NRSF, 14-3-3. DYRK1A is involved in axonal transport, neural stem cells proliferation and differentiation, and neuroinflammation. A few DYRK1A inhibitors have been tested on PD models, generally showing protective effects. The overall picture provided by this comprehensive review on the links between DYRK1A and PD advocates for more fundamental studies to understand how DYRK1A participates to the onset and development of PD and dementia with Lewy bodies (DLB), two closely related disorders. It also encourages the evaluation of well-characterized pharmacological modulators of DYRK1A as therapeutic approaches to various aspects of PD and DLB. - Source: PubMed
Publication date: 2026/04/14
Meijer LaurentLindberg Mattias FHogrel GaëlleKhor Bernard - Long non-coding RNAs (lncRNAs) have emerged as critical regulators of gene expression and play essential roles in a wide range of biological processes and human diseases, particularly cancer. () is a recently identified lncRNA transcribed from the antisense strand of the human () locus. Accumulating evidence demonstrates that is aberrantly overexpressed in multiple cancer types and is closely associated with tumor proliferation, invasion, and metastasis, etc. Mechanistically, exerts oncogenic functions through diverse regulatory modes, including transcriptional positive feedback loops, competing endogenous RNA (ceRNA) activity that sequesters tumor-suppressive microRNAs, modulation of alternative splicing and 3' end usage via interaction with hnRNPL, and epigenetic regulation of cancer-related gene expression. Moreover, the cancer- and isoform-specific expression pattern of highlights its potential utility as a diagnostic biomarker and a therapeutic target. In this review, we summarize the discovery, molecular characteristics, disease associations, and regulatory mechanisms of , and discuss its emerging clinical relevance in cancer diagnosis, prognosis, and targeted therapy. - Source: PubMed
Publication date: 2026/03/12
Zhou LiJin YizhouLi ZedongDong HaiyangJin Yongfeng - Ocular Behcet disease (OBD) is a severe sight-threatening complication of Behcet disease (BD) with a poorly understood etiology, particularly in underrepresented populations such as Pakistan. It often arises from a combination of genetic predisposition, environmental triggers, and immune dysregulation. To address this gap, we explored genetic variants contributing to ocular involvement using whole-exome sequencing (WES). - Source: PubMed
Publication date: 2026/02/23
Waqas AyeshaYasmin AzraWatson Christopher MarkAhmed IbrarSavic Sinisa - The signal pathways mediated by axon guiding molecule netrin-1 (NTN1) are transduced via its several membrane-bound receptors that include deleted in colorectal cancer (DCC), UNC5 (A-D), neogenin 1 (Neo1), melanoma cell adhesion molecule (MCAM), and Down syndrome cell adhesion molecule (DSCAM). Most of these genes play a role in the occurrence and progression of some solid tumors. Sufficient systematic studies have not been performed on the expression characteristics of the role of NTN1 and its receptors in the context of pan-cancer. Based on data from 10,437 subjects with 33 types of solid tumors in The Cancer Genome Atlas, we systematically analyzed the tumor molecular biological characteristics of NTN1 and its receptors through bioinformatics. Candidate small-molecule drugs were identified based on molecular docking analysis. Netrin-1 and its receptors exhibited stereotypical genetic alterations in tumor-suppressor genes or oncogenes. Promoter methylation and miRNA-mediated post-transcriptional inhibition likely represent the primary regulatory mechanisms, whereas the promotion of epithelial-mesenchymal transition (EMT) emerges as a conserved cellular function. we predicted potential small-molecule drugs that could bind to Netrin1 receptors. NTN1 and its receptors can be used as potential targets for tumor immunotherapy. Our results showed the important cancer biological functions of NTN1 and its receptors and their transformational value as candidate tumor biomarkers. This study also showed some critical potential immune-related therapeutic targets and provided a basis for future studies on their role in clinical immunotherapy. - Source: PubMed
Publication date: 2025/12/17
Gao YingHu YuchenZhu YuyanGao XiaoliHao WenjunChen XiZheng Zhendong - Autism spectrum disorders (ASD) represent a substantial social problem affecting at least 1 in 100 children worldwide. These conditions are very often accompanied by intellectual disability (ID) and speech delay; thus, they can be considered within a clinical continuum of neurodevelopmental disorders. Given the high heterogeneity of ASD, the subjective nature of diagnostic criteria, and the presence of phenocopies, identifying genetic determinants of these disorders remains a challenge. - Source: PubMed
Publication date: 2025/12/09
Suspitsin Evgeny NMalysheva Kristina SLaptiev Sergey ASharonova Olga SAbuzova Anastasiya SKuznitsyna Anastasiya AMelashenko Tatyana VEfremova Oksana VKorzun Polina RBinnatova Jeyla OGorgul Yuliy ASyomina Maria VImyanitov Evgeny N